Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Outlook 2025–2034

The global Alpha-1 Antitrypsin Deficiency (AATD) Treatment market is projected to grow at a CAGR of 9.5% during the forecast period 2025–2034. AATD affects approximately 0.025% of the general population, with Europe and North America emerging as key regions due to higher disease prevalence. In contrast, Asia reports comparatively lower incidence rates. The market is being driven by advancements in targeted therapies, improved diagnostic tools, and increased awareness regarding this rare genetic condition.